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Abstract
Background: Cranial irradiation is associated with long-term cognitive changes. Cerebral microbleeds (CMBs) have
been identified on susceptibility-weighted MRI (SWI) in patients who have received prior cranial radiation, and serve
as radiographic markers for microvascular injury thought to contribute to late cognitive decline. The relationship
between CMB formation and radiation dose has not previously been quantified.
Methods: SWI was performed on 13 patients with stable WHO grade III-IV gliomas between 2 and 4 years after
chemoradiotherapy to 60 Gy. The median age at the time of treatment was 41 years (range 25 – 74 years). CMBs
were identified as discrete foci of susceptibility on SWI that did not correspond to vessels. CMB density for low
(<30 Gy), median (30–45 Gy), and high (>45 Gy) dose regions was computed.
Results: Twelve of 13 patients exhibited CMBs. The number of CMBs was significantly higher for late (>3 years from
treatment) compared to early (<3 years) timepoints (early median 6 CMBs; late median 27 CMBs; p = 0.001), and
there were proportionally more CMBs at lower doses for late scans (p = 0.006). 88% of all CMBs were observed in
regions receiving at least 30 Gy, but the CMB density within medium and high dose regions was not significantly
different (p = 0.33 and p = 0.9, respectively, for early and late time points).
Conclusions: CMBs predominantly form in regions receiving at least 30 Gy, but form in lower dose regions with
longer follow-up. We do not observe a clear dose–response relationship at doses above 30 Gy. These findings
provide important information to assess the risk of late microvascular sequelae from cranial irradiation.
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Introduction
Radiotherapy plays an integral role in the management
of gliomas. Combined adjuvant chemoradiotherapy
(CRT) constitutes the standard of care after maximal
safe resection in malignant glioma [1], and is gaining ac-
ceptance as adjuvant treatment for high-risk, low-grade
gliomas [2]. Due to pathologic studies demonstrating
microscopic spread beyond tumor visible on imaging
[3–5], radiotherapy targets generally constitute a margin
of approximately 2 cm around gross visible disease and
surgical resection cavities. Thus, even with modern con-
formal radiotherapy techniques, a significant amount of
normal brain tissue receives the prescription dose of
60 Gy, with an even larger surrounding region irradiated
to lower doses [6].
Given the amount of normal irradiated brain tissue,
late toxicity from radiotherapy for gliomas is of signifi-
cant concern, particularly for patients with lower-grade
gliomas for whom survival can extend well over 10 years
[2]. Cognitive testing of long-term glioma survivors has
shown significant decline across multiple cognitive do-
mains [7], although evidence exists for tumor progres-
sion as a driver of cognitive decline in glioma patients
[8]. Reliable markers of late radiation toxicity are needed
to better characterize the mechanism of white matter
damage as well as patient, tumor, and treatment factors
that influence the risk of late cognitive decline.* Correspondence: Janine.Lupo@ucsf.edu2Department of Radiology and Biomedical Imaging, University of California,
San Francisco, CA, USA
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Studies with primate [9] and murine models [10], as
well as human autopsy studies [11, 12], have demon-
strated that microvascular damage is a prominent patho-
logic component of radiation-induced brain injury, with
endothelial degeneration leading to the formation cere-
bral microbleeds (CMBs). CMBs have also been ob-
served in elderly patients without known underlying
pathology [13, 14], as well as in other degenerative cen-
tral nervous system conditions, including cerebral amyl-
oid angiopathy (CAA) associated with Alzheimer’s
disease and vascular cognitive impairment [11], where
they have been linked to cognitive dysfunction [15–18].
Thus, quantification of CMB characteristics may serve
as a valuable metric for radiation-induced vasculopathy
and resultant cognitive decline.
Susceptibility-Weighted Imaging (SWI) is a powerful,
noninvasive tool for detecting hemosiderin-containing
CMBs, and has been utilized in several studies of stroke
and vascular injury [19–24]. Previous studies with SWI
in patients with gliomas demonstrated that CMBs ap-
peared in irradiated patients starting approximately two
years after treatment, with an increasing number of le-
sions over time; in contrast, patients with gliomas who
did not receive radiotherapy did not develop CMBs [25].
Early CMBs were generally observed in the area of rela-
tively high-dose radiation, while CMBs that appeared
later extended to lower-dose regions, including contra-
lateral cerebral hemispheres. Administration of anti-
angiogenic therapy during the course of radiation has
also been shown to decrease the rate of CMB formation
[26]. Finally, the formation of CMBs has been associated
with neurocognitive dysfunction in both pediatric and
adult patients undergoing radiotherapy [27, 28].
While these studies have suggested an association be-
tween radiation dose and CMB formation [29–31], the
precise quantitative relationship between radiation dose
and the risk of CMB formation is largely uncharacter-
ized. The purpose of this study was to directly relate
CMB characteristics to radiation dose received.
Materials and methods
Patients and treatment
Thirteen patients with newly diagnosed malignant gli-
omas were included in this retrospective study. 10 pa-
tients had histologically confirmed WHO grade IV
glioblastoma, while the remaining 3 patients had WHO
grade III gliomas (1 anaplastic astrocytoma, 1 anaplastic
oligodendroglioma, 1 anaplastic oligoastrocytoma). Me-
dian patient age at the time of radiotherapy was 41 years
(range 25 – 74 years). All patients underwent resection
followed by focal radiotherapy to a total dose of 60 Gy
in 30 daily fractions to the gross residual tumor and sur-
gical resection cavity, with a margin determined by the
treating physician but typically approximately 2 cm, and
received concurrent and adjuvant temozolomide; six pa-
tients underwent treatment with additional investiga-
tional agents, including enzastaurin (4 patients) or
bevacizumab and erlotinib (2 patients). Single time point
or serial MR imaging with SWI was performed approxi-
mately 2 to 4 years after treatment (median 27 months;
range 22 – 52 months), for a total of 18 MRIs, with 3 of
the 13 patients undergoing multiple scans. One patient
was excluded from analysis due to the early formation of
numerous microbleeds away from the radiotherapy re-
gion felt to be most consistent with an alternate etiology.
All patients provided informed consent in accordance
with guidelines established by our institutional review
board.
MRI acquisition
SWI was performed on a GE whole-body 3 T scanner
(GE Healthcare Technologies, Milwaukee, WI) with vol-
ume excitation and eight-channel phased-array reception
(Nova Medical, Wilmington, MA). A three-dimensional
(3D) spoiled gradient echo (SPGR) sequence was applied
with echo time/repetition time (TE/TR) of 28 ms/56 ms,
flip angle 20°, 24 × 24 cm2 field of view, and 2 mm slice
thickness. To keep the scan time under 7 min, a general-
ized autocalibrating partially parallel acquisition was
used with a two-fold reduction factor, 512 × 144 ac-
quired matrix, 0.5 × 0.5-mm reconstructed in-plane
resolution, and 16 autocalibrating lines [32]. Standard
clinical pre- and post-gadolinium T1-weighted 3D SPGR
and T2-weighted fluid attenuated inversion recovery im-
ages were acquired for anatomic comparison.
Data processing and analysis
The complex k-space data from all eight channels of the
3 T SWI scan were transferred off-line, and postproces-
sing was performed using in-house programs developed
with MATLAB 12.0 software (MathWorks, Natick, MA)
on a Linux cluster. Standard SWI postprocessing was
performed on the reconstructed k-space data for each
coil, which were then combined, intensity-corrected, and
projected through 8-mm-thick slabs [21]. Phase images
were created as previously described by our group [33].
For all patients, radiation dosimetry maps were retrieved
on a Pinnacle treatment planning system (Phillips Medical
Systems, Andover MA). The non-contrast CT scan ob-
tained for radiotherapy treatment planning was aligned to
the SWI image using affine registration after skull strip-
ping of both images [34, 35]. This transformation was
then applied to the radiation dosimetry map to allow
registration of radiation dose to the SWI.
CMBs were manually identified on SWI as discrete
foci of susceptibility that did not correspond to vessels
or surgical cavity on consecutive axial slices. There were
no type I-III cavernomas seen in our analysis. Although
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it is possible that type IV cavernomas were included in
the analysis, as the mechanism behind type IV caver-
noma formation is thought to be similar to microbleeds,
this is unlikely since all microbleeds observed in this
study were less than 5 mm in diameter and from our
prior experience most do not grow larger than that as
far as 15 years post –RT. Filtered phase images were
used to confirm the absence of calcifications from the
analysis. The number of microbleeds was counted in
normal-appearing tissue, outside the contrast-enhancing
tumor region and any areas of acute hemorrhage. In
order to minimize user error from counting, microbleeds
from each dataset were labeled and iteratively counted
multiple times, until the same number of counts was ob-
tained from 2 consecutive trials as performed by Lupo et
al. [25]. The maximum number of iterations required for
all patients was 4, and the counter was blinded to the
date of RT.
For each scan, the number of labeled CMBs was
counted in multiple regions: within the entire SWI vol-
ume, within prespecified radiation dose regions (low:
<30 Gy, medium: 30–45 Gy and high: >45 Gy), and
within each cortical lobe as defined using the standard-
ized Montreal Neurologic Institute (MNI) atlas [36].
Microbleed Density (MD) was then calculated as the ra-
tio of the total number of CMBs within a doismetric re-
gion to the total volume of that region, excluding areas
of surgical cavity or contrast enhancement. To account
for dose heterogeneity between cortical lobar regions,
the ratio of total number of CMBs within a lobar region
to the volume of that region receiving at least 30 Gy was
calculated (MDV30). Dosimetric parameters including
the brain volume receiving at least 30, 45 and 60 Gy
(V30, V45 and V60, respectively) were calculated and
correlated with CMB count. For analysis, scans were
grouped according to timing of scan after treatment,
with scans under 3 years characterized as “early” (9 pa-
tients, 9 scans, median time after treatment 2.0 years),
while all scans ≥3 years as “late” (5 patients, 7 scans, me-
dian time after treatment 3.5 years). Two patients under-
went scans at both the 3 and 4 year timepoints; both
scans were included in the analysis.
Statistical design
Comparisons of CMB counts and densities between
timepoints and categorical patient variables were per-
formed using a Wilcoxon rank-sum test, while correla-
tions between CMB counts and continuous patient
variables were performed using a Spearman’s ρ. The
Kolmogorov-Smirnov test was used to evaluate for a dif-
ference between the distribution of CMBs as a function
of dose as a continuous variable at early and late time-
points, while the Chi squared test was used to evaluate
the relative frequency of CMBs in low, medium and
high-dose regions at early and late timepoints. Differ-
ences in distribution of CMBs within cortical lobes be-




Example CMBs are shown in Fig. 1. CMBs were observed
in all but one patient, with a median CMB count of 9
(range: 0 and 70). A total of 306 CMBs were observed
(Table 1). The number of CMBs was observed to increase
with time, with patients scanned after 3 years demonstrat-
ing significantly more CMBs than those scanned at or be-
fore 3 years (median CMB count: 27 vs 6; p = 0.001). The
three patients who underwent scans at both timepoints all
demonstrated substantially increased CMB counts with
the later scan (25, 25 and 71 vs 4, 2 and 21). For both early
and late timepoints, CMB count was not associated with
patient age (early: Spearman’s ρ = −0.109, p = 0.78; late:
Spearman’s ρ = 0.514, p = 0.24) or the use of anti-
angiogenic therapy (early: p = 0.81; late: p = 0.48).
Radiation dose
The distribution of CMBs by dose is shown in Fig. 2; the
vast majority of all CMBs (88%) were observed at doses
over 30 Gy. However, the distribution of CMBs by dose
was significantly different between early and late time-
points (p = 0.006, Fig. 2c), with a relative shift towards
formation of CMBs at lower dose at the later timepoints.
Binned into low (<30 Gy), medium (30–45 Gy) and high
dose (>45 Gy) regions, the proportion of MBs in each
dose region at the early timepoint was 3%, 12% and 85%,
respectively; the corresponding proportions at the late
timepoint was 15%, 22% and 64%, respectively; these
proportions were significantly different (p < 0.001). At
the early timepoint, only 2 of 9 patients exhibited micro-
bleeds in the low dose region.
To account for differences in brain size, the number of
CMBs within each dose region was then normalized by
the total volume of that region to generate a metric of
microbleed density (MD). MD in each dose region for
early and late timepoints are shown in Fig. 3. The dens-
ity within each dose region was significantly higher at
late timepoints (high: p < 0.001, medium: p = 0.001, low:
p < 0.001). Comparing dose regions within each time-
point, the density of CMBs within the medium and
high-dose regions were significantly higher than that in
the low dose region (Early: medium vs low p = 0.006,
high vs low p = 0.001; Late: medium vs low p < 0.001,
high vs low p < 0.001). However, no significant differ-
ence in density between the medium and high-dose re-
gions were observed (Early: medium vs high p = 0.33,
Late: medium vs high p = 0.9).
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The relationship between the number of CMBs and
dosimetric parameters, including the volume of brain re-
ceiving at least 30 Gy (V30), 45 Gy (V45) and 60 Gy
(V60) were examined. At early time points, the total
number of CMBs seen in each patient was significantly
correlated with the V30 (Spearman’s ρ = 0.68, p = 0.045)
and V45 (Spearman’s ρ =0.78, p = 0.01), with a trend to-
wards correlation with V60 (Spearman’s ρ = 0.63,
p = 0.07). However, there were no significant correla-
tions between V30, V45 or V60 and number of CMBs at
later timepoints (Spearman’s ρ = 0.23, 0.31, −0.05 and
p = 0.61, 0.50, 0.91, respectively).
Anatomic location
The tumors were located primarily in frontal and tem-
poral lobes (5 frontal lobe, 4 temporal lobe, 1 parietal
lobe, 2 occipital lobe, 1 thalamic). The total number of
CMBs observed in each cortical lobe is reported in Table
1. In order to account for variation in the distribution of
radiation dose across the lobar volumes, the CMB count
was normalized by the volume of each lobe receiving at
least 30 Gy (V30) to calculate a microbleed density
(MDV30). While qualitatively there appeared to be a
lower microbleed density in frontal and occipital lobes,
the distribution of MDV30 was not significantly different
between lobes (p = 0.29 and p = 0.30 for early and late
time points, respectively).
Discussion
Adjuvant radiotherapy remains the standard of care for
all patients with newly diagnosed WHO grade III and IV
gliomas, and is increasingly used for patients with WHO
grade II gliomas [1, 2]. Due to the large amount of nor-
mal brain tissue encompassed in radiation fields for
gliomas, a major late complication of treatment is long-
term cognitive decline. While progressive decline has
been demonstrated in patients with glioma undergoing
radiotherapy [7], particularly for those with WHO grade
II gliomas with long overall survival, the patient and
treatment factors that increase the risk of cognitive de-
cline are not well defined. Cerebral microbleeds (CMBs)
have been previously observed in patients undergoing
radiotherapy [25–27, 29–31], and have been linked to
cognitive decline [27, 28]. However, the precise relation-
ship between radiation dose and CMB formation has not
been characterized.
Fig. 1 Example Microbleeds. (a) and (b) demonstrate example patients with SWI images obtained at early (left) and late (right) timepoints, demonstrating
progression in the number and distribution of CMBs between scans
Table 1 Summary of total CMB counts and densities across all subjects by anatomic and dosimetric region. For lobar regions, density
calculations are normalized to the volume of each lobe receiving at least 30 Gy (MDV30). Units of CMB density are given in CMBs/dm
3
1-2 Years 3-4 Years
Region Total CMB Count Median CMB Density (range) Total CMB Count Median CMB Density (range)
Whole Brain 66 4.43 (0.68 – 12.4) 240 23.0 (15.5 - 47.4)
<30 Gy 2 0 (0–1.48) 35 6.41 (2.48 – 14.6)
30-45 Gy 8 5.7 (0 – 14.1) 52 32.9 (28.9 – 74.7)
>45 Gy 56 9.51 (0 – 27.0) 154 47.6 (24.8 – 97.6)
Frontal Lobe 6 0 (0–6.30) 50 29.1 (0.0 – 70.3)
Parietal Lobe 19 8.27 (0–45.9) 58 75.3 (26.9 – 135)
Occipital Lobe 6 0 (0 – 38.1) 35 37.9 (0 – 97.8)
Temporal Lobe 9 5.10 (0 – 30.7) 26 67.1 (0 – 318)
Periventricular White Matter 26 7.7 (0–30.2) 71 53.9 (0 – 152)
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In this study, we performed the first quantitative assess-
ment of the effect of radiation dose on microbleed forma-
tion, demonstrating a time-dependent relationship between
microbleed formation and dose, with an increasing propor-
tion of microbleeds forming in lower dose regions with in-
creasing time from receipt of radiotherapy. This finding is
consistent with prior qualitative observations that patients
scanned at later timepoints are more likely to have micro-
bleeds present in the cerebral hemisphere contralateral to
their initially irradiated lesion [25]. The incidence of micro-
bleeds increased significantly at all dose levels between 2
and 4 years after treatment, highlighting that microbleed
formation represents a late sequelae of radiation that can
take years to fully manifest, consistent with the clinically
observed time course for the development of cognitive
decline [37].
Collectively, these results are consistent with a dose-
latency effect in CMB formation: CMBs appear to form
with relatively short latency in high-dose regions, with
longer latency seen in areas receiving lower radiation
dose. While the precise radiobiologic mechanism for this
dose-latency effect has not been elucidated, we
hypothesize that different mechanisms for CMB forma-
tion may be involved in low and high-dose regions. Spe-
cifically, direct endothelial damage on a relatively short
time scale may dominate in high-dose regions, while in-
direct effects on vasculature with a longer latency
period, including vascular proliferation, perivascular fi-
brosis and chronic microglial activation, may dominate
in low-dose regions [9]. Further study of this dose-
latency effect is warranted.
Although there was a trend towards increased micro-
bleed density over 45 Gy, the density within regions re-
ceiving moderate dose (30–45 Gy) was overall similar to
that observed in high-dose regions (>45 Gy), compared
to the reduced CMB density within low-dose regions
(<30 Gy). These results suggest that the risk of CMB for-
mation does not increase linearly with dose, particularly
at later timepoints, arguing for a ceiling effect for CMB
formation hypothesized in other studies [31], though a
study with a larger cohort would be required to probe
the dose–response relationship above 30 Gy in more de-
tail. We also found that, at early timepoints, the total
volume of brain receiving relatively low dose (V30 and
V45) was a better dosimetric predictor of the risk of
CMB formation than the high-dose region (V60). Thus
V30 could be a useful metric clinically to assess risk of
microvascular damage. Given that the 30 Gy volume was
relatively large in patients undergoing radiotherapy for
gliomas, these results highlight that areas at significant
risk of CMB formation may be far from the site of the
tumor and resultant high-dose region. Our findings are
also consistent with the observed CMB formation and
cognitive decline in patients undergoing whole brain
radiotherapy, where a modest dose of 30 – 37.5 Gy (cor-
responding to 38–42 Gy in standard fractionation) is
typically given [38, 39].
Although the density of CMBs within regions receiving
under 30 Gy was relatively low initially, CMBs were still
observed within these regions, particularly at later time-
points. These results are consistent with a prior study
Fig. 2 Distribution of microbleeds by dose. a, b) Histogram of
microbleeds vs dose at the early (<3 years) and late (≥3 years)
timepoints, respectively. c) Cumulative distribution function of
microbleed formation by dose for early (solid) and late (dashed)
timepoints. The distribution between the two timepoints was
significantly different by a Kolmogorov-Smirnov test (p = 0.006)
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showing a high rate of CMB formation outside the re-
gion of high-dose radiation in pediatric patients [31].
Crucially, this study featured very long follow-up, with
median follow-up of over 11 years, suggesting that the
risk of CMB formation in low-dose regions may con-
tinue to increase for many years after radiotherapy, while
a ceiling effect may prevent further formation of CMBs
in high dose regions with longer follow-up. These find-
ings together are of significant clinical importance, sug-
gesting that pediatric patients undergoing low-dose
radiotherapy, such as craniospinal radiation to a dose of
24 Gy for medulloblastomas, are at risk for late micro-
vascular damage from treatment.
While we observed qualitatively fewer microbleeds in
frontal and occipital lobe regions, we did not see a sig-
nificant variation in microbleed density between lobar
regions. However, this comparison may be confounded
by the differing distribution of tumors within each lobe,
and limited by our relatively small cohort. While the dis-
tribution of microbleeds in patients with Cerebral Amyl-
oid Angiopathy demonstrated a specific lobar pattern of
microbleed formation within temporal and occipital
lobes [40], it is unclear whether there are underlying
anatomic or functional differences between brain regions
that confer variable susceptibility to microvascular dam-
age by radiation.
In our study with a small patient cohort, we did not
find any individual patient factors that were predictive of
CMB formation. Specifically, no association between age
or use of anti-angiogenic therapy was found. The lack of
association with age has been seen in previous studies,
but an association between anti-angiogenic therapy and
decreased risk of CMB formation was previously ob-
served [26]. However, our small cohort size limits any
conclusions regarding individual patient risk factors for
CMB formation.
Several limitations of our studies should be mentioned.
First, our patient population was relatively heteroge-
neous, specifically with some patients undergoing
experimental anti-angiogenic treatment, potentially lim-
iting the generalization of our results. Second, the scan
coverage of the entire brain was variable across the
study, with images obtained early in the study lacking
the full-brain coverage that was achieved with more ro-
bust parallel imaging routines implemented for more re-
cent scans. For patients with microbleeds near the edge
of the imaged volume, this limitation could potentially
alter our estimation of both microbleed counts and the
density of microbleeds within regions that were only
partially evaluable for the presence of microbleeds.
Third, since microbleeds were visually identified for each
scan, there is the possibility of human error in lesion
identification. It can be challenging to differentiate an en
face vessel from a microbleed; however the contiguous
slice coverage of the 3D scan and minimum-intensity
projections limited this source of error. In addition,
CMBs were iteratively counted until a consistent count
was achieved. Finally, our study did not include longitu-
dinal neurocognitive assessment for correlation with
radiographic findings.
Further work is needed to better characterize CMBs
and their clinical importance. First, while we demon-
strate substantial patient variability in the rate of CMB
formation, studies with larger cohorts are needed to
identify specific patient factors that confer an increased
risk of CMB formation. Second, the link between CMB
formation and cognitive decline needs to be elucidated
further. Specifically, the relationship between CMB for-
mation in specific brain regions and cognitive decline is
not well established, and it remains unclear whether
CMB formation precedes the development of cognitive
changes in a potentially clinically actionable manner.
Fig. 3 CMB density by dose. Boxplot of CMB densities for each subject in low, medium and high-dose regions at early (a) and late (b) timepoints.
Significant differences between dose regions by Wilcoxon rank-sum tests are shown; *p < 0.05. **p < 0.01
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Conclusions
We have demonstrated dosimetric and temporal vari-
ability in the risk of formation of cerebral microbleeds
after chemoradiotherapy for patients with malignant gli-
omas. Microbleeds formed predominantly within regions
receiving at least 30 Gy of radiation without a clear
dose–response relationship at higher doses, and in-
creased in density with time from treatment. Our find-
ings have important implications for the understanding
of late microvascular sequelae of cranial irradiation, and
may be clinically useful in assessing an individual pa-
tient’s risk of microbleed formation and resultant poten-
tial cognitive decline. Further work is needed to analyze
the link between CMB formation and long-term cogni-
tive changes in patients undergoing radiotherapy, and to
determine individual patient factors that confer in-
creased risk of CMB formation and long-term micro-
vascular damage.
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